Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Boosted by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 134,762 shares of the biopharmaceutical company’s stock after purchasing an additional 9,472 shares during the quarter. Canada Pension Plan Investment Board owned about 0.12% of Regeneron Pharmaceuticals worth $141,639,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 1.0% in the first quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after purchasing an additional 91,956 shares in the last quarter. Capital World Investors increased its stake in Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock valued at $4,506,071,000 after buying an additional 23,146 shares during the period. Capital International Investors raised its position in shares of Regeneron Pharmaceuticals by 7.3% during the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after buying an additional 213,038 shares in the last quarter. Putnam Investments LLC lifted its stake in shares of Regeneron Pharmaceuticals by 2.1% in the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after acquiring an additional 24,329 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Regeneron Pharmaceuticals by 25.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after acquiring an additional 184,561 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

REGN has been the topic of several recent analyst reports. Guggenheim boosted their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Barclays upped their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 10th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Finally, JPMorgan Chase & Co. increased their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $1,111.30.

Regeneron Pharmaceuticals Trading Down 0.4 %

NASDAQ REGN opened at $1,145.03 on Friday. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20. The firm’s fifty day simple moving average is $1,131.75 and its 200-day simple moving average is $1,031.74. The company has a market capitalization of $126.17 billion, a PE ratio of 33.83, a price-to-earnings-growth ratio of 3.93 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period last year, the business earned $8.79 EPS. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 756 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at $1,467,684. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Marion Mccourt sold 1,137 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the transaction, the executive vice president now directly owns 12,931 shares in the company, valued at $13,540,179.41. The disclosure for this sale can be found here. Insiders have sold a total of 10,026 shares of company stock worth $11,498,705 in the last 90 days. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.